Findings from the GOG 158 trial has established carboplatin and paclitaxel as the standard of care for ovarian cancer for the past twenty years. Alexander Olawaiye, MD, FRCOG, FACOG, FACS, University of Pittsburgh, Pittsburgh, PA, discusses novel approaches in the management of ovarian cancer. Novel classes including anti-angiogenesis drugs such as bevacizumab, and anti-PARP drugs have considerably improved outcomes. Immunotherapies such as immune checkpoint inhibitors and antibody-drug conjugates have additionally provided alternative treatment strategies for patients. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.